Edwards Lifesciences (NYSE:EW) Issues Q3 2026 Earnings Guidance

Edwards Lifesciences (NYSE:EW) updated its third quarter 2026 earnings guidance on Thursday morning. The company provided earnings per share (EPS) guidance of 0.710-0.770 for the period, compared to the consensus EPS estimate of 0.740. The company issued revenue guidance of $1.6 billion-$1.7 billion, compared to the consensus revenue estimate of $1.7 billion. Edwards Lifesciences also updated its FY 2026 guidance to 2.950-3.050 EPS.

Analysts Set New Price Targets

A number of brokerages have commented on EW. Citigroup increased their target price on Edwards Lifesciences from $101.00 to $110.00 and gave the company a “buy” rating in a report on Wednesday, July 8th. Wall Street Zen cut Edwards Lifesciences from a “buy” rating to a “hold” rating in a report on Saturday, July 4th. Mizuho upped their price objective on Edwards Lifesciences from $100.00 to $105.00 and gave the company an “outperform” rating in a research report on Wednesday, July 15th. Canaccord Genuity Group set a $85.00 price objective on Edwards Lifesciences and gave the company a “hold” rating in a research note on Friday, April 24th. Finally, Leerink Partners upgraded Edwards Lifesciences from a “market perform” rating to an “outperform” rating and set a $101.00 price objective for the company in a research report on Friday. One investment analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and seven have given a Hold rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $99.55.

Edwards Lifesciences Trading Down 1.4%

Shares of Edwards Lifesciences stock opened at $82.67 on Friday. Edwards Lifesciences has a fifty-two week low of $72.30 and a fifty-two week high of $96.29. The firm has a market cap of $47.60 billion, a PE ratio of 47.51, a P/E/G ratio of 2.10 and a beta of 0.86. The business’s fifty day moving average is $87.73 and its two-hundred day moving average is $83.88. The company has a quick ratio of 3.63, a current ratio of 4.42 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings data on Thursday, July 23rd. The medical research company reported $0.78 EPS for the quarter, beating analysts’ consensus estimates of $0.74 by $0.04. The business had revenue of $1.74 billion during the quarter, compared to the consensus estimate of $1.70 billion. Edwards Lifesciences had a return on equity of 15.85% and a net margin of 15.43%.The business’s revenue for the quarter was up 13.6% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.67 earnings per share. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. Analysts anticipate that Edwards Lifesciences will post 3 earnings per share for the current year.

Insider Buying and Selling at Edwards Lifesciences

In related news, VP Donald E. Bobo, Jr. sold 23,145 shares of the firm’s stock in a transaction that occurred on Wednesday, May 27th. The shares were sold at an average price of $86.42, for a total value of $2,000,190.90. Following the sale, the vice president directly owned 98,611 shares of the company’s stock, valued at approximately $8,521,962.62. This trade represents a 19.01% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Andrew M. Dahl sold 568 shares of the business’s stock in a transaction that occurred on Friday, May 29th. The shares were sold at an average price of $86.08, for a total transaction of $48,893.44. Following the completion of the sale, the senior vice president owned 15,334 shares of the company’s stock, valued at approximately $1,319,950.72. The trade was a 3.57% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 45,577 shares of company stock worth $3,855,527 in the last 90 days. 0.31% of the stock is owned by company insiders.

Key Headlines Impacting Edwards Lifesciences

Here are the key news stories impacting Edwards Lifesciences this week:

• Positive Sentiment: Edwards Lifesciences beat Q2 estimates on both earnings and revenue, with sales rising 13.6% year over year to $1.74 billion, helped by strong demand for heart-valve products and growing adoption of mitral and tricuspid therapies.
• Positive Sentiment: The company raised the low end of its full-year revenue outlook to $6.6 billion-$6.9 billion and also lifted its TAVR growth guidance, signaling management confidence in continued momentum.
• Positive Sentiment: Analysts turned more constructive after the report: JPMorgan raised its price target to $105 and kept an overweight rating, while Leerink upgraded the stock to outperform with a $101 target.
• Positive Sentiment: Commentary from Wall Street framed the quarter as evidence that Edwards remains a top medtech growth story, with its core TAVR franchise and newer structural heart therapies driving the upside.
• Neutral Sentiment: The company’s updated Q3 and full-year EPS guidance was broadly in line with expectations, suggesting the current move is being driven more by sales strength and sentiment than by a major earnings surprise.

Hedge Funds Weigh In On Edwards Lifesciences

Hedge funds have recently made changes to their positions in the stock. JPL Wealth Management LLC purchased a new position in shares of Edwards Lifesciences in the 3rd quarter worth $25,000. Kemnay Advisory Services Inc. purchased a new stake in Edwards Lifesciences during the fourth quarter valued at about $27,000. Rakuten Securities Inc. grew its position in Edwards Lifesciences by 413.7% during the second quarter. Rakuten Securities Inc. now owns 375 shares of the medical research company’s stock valued at $29,000 after acquiring an additional 302 shares during the period. Kelleher Financial Advisors acquired a new stake in Edwards Lifesciences during the third quarter worth about $50,000. Finally, Chapman Financial Group LLC acquired a new stake in Edwards Lifesciences during the second quarter worth about $63,000. Institutional investors and hedge funds own 79.46% of the company’s stock.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.